Johnson & Johnson is significantly boosting its commitment to the United States, with CEO Joaquin Duato crediting the Trump administration’s tax policies as a key driver for a $55 billion investment in U.S. manufacturing and research.
“We have the best talent, we have the best investment environment and, very importantly, we have now the tax policy enacted with this administration that has enabled us to be competitive,” Duato stated on FOX Business’ “Mornings with Maria.” He emphasized that prior tax structures had put U.S. companies at a disadvantage compared to international competitors.
The company’s renewed focus on domestic production includes a substantial investment of over $1 billion in a U.S. Vision manufacturing facility located in Jacksonville, Florida. Duato framed these investments as a strong vote of confidence in American manufacturing capabilities.
Johnson & Johnson’s strategic direction has shifted following the divestiture of its consumer health segment. The company is now concentrating on its core businesses in medical technology and pharmaceuticals, aiming to drive sustained growth through scientific innovation and patient breakthroughs.
Duato highlighted recent advancements, including the approval of Icotyde, a new oral treatment for psoriasis and psoriatic arthritis, which is expected to significantly impact the treatment of autoimmune diseases. On the medical technology front, the company is pursuing approval for its first robotic surgical system designed to enhance surgical outcomes.
With a robust portfolio of 28 platforms each valued at over $1 billion, Johnson & Johnson anticipates achieving double-digit growth by the end of the decade, a remarkable projection for a company with revenues exceeding $100 billion.
About the Author
